Antigen & Antibody Rapid Test Kit — Technical Guide for Research and Surveillance Workflows

Antigen & Antibody Rapid Test Kits” are lateral flow immunoassays (LFIAs) designed to detect either pathogen antigens (e.g., nucleocapsid proteins) or host antibodies (IgM/IgG/total Ig) in minutes. This guide focuses on research, surveillance, and method-comparison contexts and avoids clinical claims. Background primers on serologic and antigen testing are available from CDC (serologic testing overview) and FDA (general IVD guidance portal). For immunoassay fundamentals, see NIH/NCBI Bookshelf (Medical Microbiology: Immunoassays) and NIST notes on measurement assurance in diagnostics (NIST IVD measurement science).

Principles of operation

Antigen rapid tests

Antigen LFIAs employ capture antibodies striped on nitrocellulose and detection antibodies conjugated to colloidal gold/latex. When a sample containing target antigen flows by capillarity, sandwich complexes accumulate at the test line. See CDC’s antigen-test explainer (overview) and NIH/NCBI immunology chapters (Bookshelf).

Antibody rapid tests

Antibody LFIAs immobilize pathogen antigens (or anti-human Ig) on the test line to capture host IgM/IgG. Interpretation depends on seroconversion kinetics and class switching. See CDC (antibody testing basics) and MedlinePlus/NIH (serology testing background).

Control line & flow validity

A procedural control line binds excess conjugate (e.g., anti-species) to confirm adequate sample flow and reagent integrity. Practical line chemistry and membrane properties are discussed in NIST method publications (membrane flow considerations) and university teaching notes (e.g., UW lecture materials on LFIAs: washington.edu).

Kit components (typical)

Test cassettes with nitrocellulose membranes (test/control lines), conjugate pad, sample pad, absorbent pad.
Extraction/dilution buffer optimized for antigen stability or antibody binding.
Dropper or swab (for antigen tests) or pipette tips (serum/plasma/whole blood).
Positive/negative controls for QC.
IFU with read window (e.g., 10–20 min).
Reference frameworks for IFU content and labeling are available from FDA (labeling & IFU resources) and CDC quick guides (point-of-care testing overview).

Sample matrices & pre-analytical effects

Antigen kits: usually nasal/nasopharyngeal swabs or other validated matrices; Antibody kits: serum, plasma, or whole blood (EDTA/heparin). Matrix interferences (hemolysis, lipemia, viscosity) can alter flow and line development. See CDC specimen handling guidance (specimen collection basics) and University of Minnesota diagnostics pages for sample acceptability (UMN VDL sample guidance). For general biospecimen management, NIH/NCI offers pre-analytical variable guidance (NCI biospecimen best practices).

Analytical performance and verification

Definitions

Analytical sensitivity (limit of detection, LOD) and analytical specificity (cross-reactivity panel).
Clinical sensitivity/specificity when compared to a reference method (e.g., culture, PCR, or established serology).
Likelihood ratios, PPV/NPV depend on prevalence.

FDA provides general evaluation considerations for LFIAs and EUA templates (antigen template, serology template). CDC details interpretation pitfalls for both test types (testing overview).

Verification study sketch (research use)

Panel selection: characterized positives/negatives across Ct/antibody-titer ranges; include potential cross-reactors.
Comparators: PCR or reference ELISA per pathogen.
Precision: inter-operator and inter-lot agreement.
Hook effect checks for high-antigen samples.
See FDA general validation resources (IVD studies) and NIH/PMC method papers on lateral flow evaluation (review article index).

Cross-reactivity, interference, and specificity risks

Cross-reactivity arises from antigenic similarity (e.g., shared epitopes) or heterophile antibodies. Interferences include rheumatoid factor, high biotin, mucin, or detergents. CDC highlights false-positive scenarios in serology (serology caveats

) and NCBI Bookshelf discusses heterophile antibody interference (clinical immunoassay interference). For antigen tests, CDC outlines confirmatory strategies and algorithmic use (antigen algorithms).

Quality control (QC) and quality assurance (QA)

Internal controls: control line presence, on-board functional controls.
External controls: positive/negative controls per lot/start of day.
Environmental conditions: temperature/humidity within IFU limits.
Documentation: lot traceability, training records, deviation logs.

Guidance is available from CDC’s CLIA resources (CLIA overview) and CMS/CLIA interpretive guidelines (CMS CLIA manual PDF). Many university labs publish POCT QA checklists (e.g., University of Washington Lab Medicine: uw.edu/labmed).

Biosafety and handling

Follow institutional biosafety rules for human specimens: BSL-2 practices, PPE, and decontamination. See CDC biosafety in microbiological labs (Biosafety in Microbiological and Biomedical Laboratories, BMBL) and NIH occupational health pages (NIH biosafety resources). For sharps and biohazard waste, see OSHA/NIH aligned references (NIH waste management).

Interpretation and algorithmic use (high-level, non-diagnostic)

Antigen LFIA: best near peak viral/bacterial load; negative results near symptom onset/late phases may require alternate methods in formal algorithms (see CDC testing overview: link).
Antibody LFIA: reflects prior exposure and seroconversion; timing matters (IgM vs IgG). CDC explains windows and limitations (antibody test info).
Serial testing / confirmation: agency algorithms often pair screen + confirmatory methods; consult FDA and public-health lab guidance (APHL/CDC testing resources).

Packaging, labeling, and stability (general expectations)

Labeling: intended use, specimen types, limitations, storage, and warnings per FDA labeling requirements (device labeling).
Stability: real-time/accelerated studies; transport stress. See FDA study design recommendations for IVDs (stability considerations).
Traceability: barcodes/UDI where applicable (FDA UDI overview).

Common pitfalls & troubleshooting

Weak test lines: verify read time window, sample volume, and buffer ratio; re-test with fresh controls.
No control line: invalid run; check membrane hydration and buffer composition.
Hook effect (antigen tests): extremely high antigen may mask line; dilute per IFU and repeat.
High background: excess viscosity or matrix components; consider pre-treatment per IFU.

For structured troubleshooting steps, see academic POCT notes from Harvard teaching labs (harvard.edu lab protocols) and Stanford biosciences methods pages (med.stanford.edu lab resources).

Primary: antigen rapid test kit, antibody rapid test kit, lateral flow immunoassay, point-of-care test cassette, IgM IgG rapid test
Secondary: antigen capture assay, serology rapid test, LFIA sensitivity specificity, cross-reactivity, hook effect, sample matrix interference, QC controls, CLIA POCT, BSL-2 biosafety
Supportive phrases: nitrocellulose membrane, colloidal gold conjugate, control line validity, lot-to-lot reproducibility, analytical validation protocol

Use primary keywords in H1/H2, first 100–150 words, image alt text (e.g., “lateral flow cassette with antigen capture line”), and internal links to your Rapid Tests and ELISA categories. Add FAQPage structured data covering matrix, read window, and QC controls.